Jagsonpal Pharmaceuticals has executed Business Transfer Agreement (BTA) with Group Pharmaceuticals (Group Pharma) for the acquisition of Group Pharma’s Wellness Portfolio on a going-concern basis by way of slump sale. The transaction is expected to be completed on or before November 1, 2026. This business brings in an established portfolio of products and an existing market presence, which it intends to integrate with its existing commercial platform and capabilities while leveraging its existing distribution network to create operating synergies.
Jagsonpal Pharmaceuticals is among India’s premiere pharmaceutical companies. The company has substantial research and development, manufacturing, marketing and distribution facilities.
